![Brendan Delaney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brendan Delaney
Director/Board Member at
BEYONDSPRING INC.
Net worth: - $ as of 2026-08-30
Profile
Brendan Delaney currently works at BeyondSpring Pharmaceuticals, Inc., as Director, BeyondSpring, Inc., as Independent Director from 2021, and MJH Healthcare Holdings LLC, as Director.
Mr. Delaney also formerly worked at Aadi Subsidiary, Inc., as President & Chief Executive Officer, Whitehawk Therapeutics, Inc., as President, Chief Executive Officer & Director in 2023, Novartis Oncology, Inc., as Director-Global Chronic Myeloid Leukemia Franchise from 2006 to 2011, Celgene Corp., as VP-US Commercial Hematology & Oncology, Immunomedics, Inc., as Chief Commercial Officer from 2017 to 2021, and Constellation Pharmaceuticals, Inc., as Chief Commercial Officer in 2021.
Mr. Delaney received his undergraduate degree from Rutgers State University of New Jersey and Masters Business Admin degree from The Leonard N Stern School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BEYONDSPRING INC. -.--% | 2026-03-31 | 0 ( -.--% ) | - $ | 2026-08-30 |
Brendan Delaney active positions
| Companies | Position | Start |
|---|---|---|
| BEYONDSPRING INC. | Director/Board Member | 2021-07-13 |
BeyondSpring Pharmaceuticals, Inc.
 BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative cancer therapies that improve clinical outcomes | Director/Board Member | - |
MJH Healthcare Holdings LLC
 MJH Healthcare Holdings LLC Internet Software/ServicesTechnology Services Operates as a health care content and educational platform | Director/Board Member | - |
Former positions of Brendan Delaney
| Companies | Position | End |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Chief Executive Officer | 2023-03-02 |
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-08-31 |
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 2020-12-31 |
| CELGENE | Corporate Officer/Principal | 2017-10-31 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | 2010-12-31 |
Training of Brendan Delaney
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
73
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BeyondSpring Pharmaceuticals, Inc.
BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative cancer therapies that improve clinical outcomes | Health Technology |
BeyondSpring, Inc.
 BeyondSpring, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cancer therapies | Health Technology |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
MJH Healthcare Holdings LLC
MJH Healthcare Holdings LLC Internet Software/ServicesTechnology Services Operates as a health care content and educational platform | Technology Services |
Aadi Bioscience, Inc.
 Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
- Stock Market
- Insiders
- Brendan Delaney
